… care for advanced non–small cell lung cancer (NSCLC) … 7.7 mo) was observed in
T790M-negative patients compared … of erlotinib for patients with stable disease on prior gefitinib …

… Erlotinib might have also been recommended as third-line in the 2009 ASCO … efficacy
in patients who received erlotinib as third-line compared with those who received erlotinib as …

… was consistent across various subgroups, the pooled efficacies for PFS, OS, and ORR were
… A phase III RCT compared gefitinib and erlotinib in EGFR mutation-positive NSCLC and …

… We compared the efficacy of cabozantinib alone or in combination with … in the second-line
and third-line setting. We did this trial to directly compare the efficacy of erlotinib with …

… and efficacy of third-line anlotinib for patients with refractory … erlotinib or gefitinib and have
a PS of 0–3, the efficacy of this … in NSCLC, although direct comparisons of AEs with other …

… gefitinib and erlotinib have both been proven effective for treating advanced non–small cell
lung cancer … compare their efficacy and safety in treating advanced NSCLC in this population. …

… , we designed this randomized, phase-2 study comparing the efficacy and tolerability of
erlotinib 100 mg/d vs. gefitinib 250 mg/d in patients with EGFR-mutated advanced NSCLC. …

… routinely used to treat non-small cell lung cancer (NSCLC) in patients with common activating
mutations of the EGFR gene. The aim of the study was to compare the efficacies of EGFR‑…

… head-to-head trials comparing treatment with gefitinib and erlotinib in patients with EGFR …
-inferiority of icotinib when compared with gefitinib in a second- or third-line treatment. Table 1 …

… for patients who have not received prior erlotinib or gefitinib … , p = 0.65) when compared to
erlotinib alone. Based on our … the efficacy of third-line therapy in the treatment of advanced …